Table 3.

Multivariate Cox regression analyses in the training and validation cohorts

OSTTR
VariablesHR (95% CI)PHR (95% CI)P
Training cohort
 AFP, ng/mL (>20 vs. ≤20)1.55 (0.89–2.69)0.1181.29 (0.76–2.18)0.351
 Tumor encapsulation (none vs. complete)1.58 (0.95–2.63)0.076NANA
 Tumor differentiation (III–IV vs. I–II)NANA1.63 (0.96–2.79)0.073
 Tumor size, cm (>5 vs. ≤5)1.90 (1.07–3.37)0.0281.88 (1.08–3.28)0.027
 Vascular invasion (yes vs. no)1.61 (0.79–3.26)0.1872.66 (1.27–5.59)0.010
 BCLC (B+C vs. 0+A)0.81 (0.38–1.76)0.5970.54 (0.25–1.20)0.129
 NLR (≥5 vs. <5)1.43 (0.73–2.78)0.2941.46 (0.73–2.90)0.284
 PLR (≥150 vs. <150)0.79 (0.41–1.53)0.4830.89 (0.49–1.62)0.697
 SII (≥330 vs. <330)2.10 (1.14–3.85)0.0171.92 (1.04–3.54)0.037
Validation cohort
 AFP, ng/mL (>20 vs. ≤20)2.65 (0.79–8.96)0.1161.86 (0.94–3.69)0.077
 Tumor encapsulation (none vs. complete)0.45 (0.20–1.01)0.0520.73 (0.42–1.29)0.276
 Tumor size, cm (>5 vs. ≤5)NANA1.41 (0.78–2.56)0.254
 Vascular invasion (yes vs. no)NANA1.25 (0.68–2.30)0.470
 BCLC (B+C vs. 0+A)NANA1.65 (0.84–3.23)0.147
 NLR (≥5 vs. <5)NANA1.32 (0.56–3.07)0.527
 SII (≥330 vs. <330)2.56 (1.17–5.76)0.0192.32 (1.28–4.23)0.006

NOTE: The clinicopathologic variables were adopted for their prognostic significance by univariate analyses.

Abbreviation: NA, not applicable.